A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

Korábbi kezelés

• Patients actively receiving insulin or patients whose doctors have recommended current insulin use
• Patients who are on the following drugs and cannot have a substitution or who decline the substitution:
  • warfarin
  • flecainide
  • methadone
  • amphetamines
  • quinidine
  • chlorpropamide
• Prior radiation therapy that would result in a field overlap

Más betegség

• Recurrent non-small cell lung cancer
• Uncontrolled, intercurrent illness
• HIV positive individuals undergoing therapy due to known drug:drug interaction between antiretroviral drugs and high-dose ascorbate therapy
  • If all the above are met, the potential participant will receive a 15 gram challenge dose of ascorbate via intravenous infusion. This is the final screening procedure.

Laborértékek

• Glucose-6-phosphate dehydrogenase (G6PD) deficiency
• Patients requiring daily finger-stick blood glucose measurements

Egyéb

• Exudative pleural effusion
• Enrolled in another therapeutic clinical trial
• Lactating women

• Note: patients who have a small pleural effusion that is too small to safety tap and is not visible on a chest x-ray are still eligible
• Pathologic diagnosis (i.e., cell sample, biopsy, tissue swap, bronchoscopy) of non-small cell lung cancer.
• Recommended to receive carboplatin \& paclitaxel with radiation therapy as a treatment
• Tumor or metastatic disease must measure at least 1 cm using a CT scan (CAT scan)
• Physician determined the patient is healthy enough for chemotherapy and radiation therapy
• At least part of the lung cancer must be viewable and measurable by CT or MRI
• A platelet count of at least 100,000 cells per mililiter
• A creatinine level of less than 1 1/2 times the upper limit of normal for the local lab test, or, a creatinine clearance of at least 60 mL/(min*1.73m2)
• Not pregnant, and commit to using birth control during the study